Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases.
Kobayashi S, Bando H, Taketomi A, Takamoto T, Shinozaki E, Shiozawa M, Hara H, Yamazaki K, Komori K, Matsuhashi N, Kato T, Kagawa Y, Yokota M, Oki E, Komine K, Takahashi S, Wakabayashi M, Yoshino T. Kobayashi S, et al. Among authors: shinozaki e. BMC Cancer. 2023 Aug 21;23(1):779. doi: 10.1186/s12885-023-11311-5. BMC Cancer. 2023. PMID: 37605122 Free PMC article. Clinical Trial.
Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer.
Nakayama I, Suenaga M, Wakatsuki T, Ichimura T, Ozaka M, Takahari D, Shinozaki E, Chin K, Ueno M, Mizunuma N, Yamaguchi T. Nakayama I, et al. Among authors: shinozaki e. Cancer Chemother Pharmacol. 2015 Jul;76(1):133-9. doi: 10.1007/s00280-015-2780-1. Epub 2015 May 21. Cancer Chemother Pharmacol. 2015. PMID: 25994854
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
Osumi H, Shinozaki E, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Yamamoto N, Mizunuma N. Osumi H, et al. Among authors: shinozaki e. BMC Cancer. 2015 Oct 21;15:760. doi: 10.1186/s12885-015-1751-6. BMC Cancer. 2015. PMID: 26490659 Free PMC article.
165 results